Molecular pharmacology of voltage-dependent calcium channels. 1996

Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
Institute of Molecular Pharmacology and Biophysics, University of Cincinnati College of Medicine, Ohio 45267-0828, U.S.A.

Voltage-dependent Ca2+ channels serve as the only link to transduce membrane depolarization into cellular Ca(2+)-dependent reactions. A wide variety of chemical substances that have the ability to modulate Ca2+ channels have been demonstrated both for their clinic utility and for importance in elucidating the molecular basis of various biological responses. Recently, introduction of molecular biology to pharmacology has brought a great deal of information about the molecular basis of drug action in Ca2+ channels. In this review, we attempt to overview recent progress in understanding the interactions between Ca2+ channels and their blockers, namely Ca2+ antagonists, from a molecular and structural point of view.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D008978 Mollusk Venoms Venoms from mollusks, including CONUS and OCTOPUS species. The venoms contain proteins, enzymes, choline derivatives, slow-reacting substances, and several characterized polypeptide toxins that affect the nervous system. Mollusk venoms include cephalotoxin, venerupin, maculotoxin, surugatoxin, conotoxins, and murexine. Conus Venoms,Octopus Venoms,Snail Venoms,Conus Venom,Mollusc Venoms,Mollusk Venom,Octopus Venom,Snail Venom,Venom, Conus,Venom, Mollusk,Venom, Octopus,Venom, Snail,Venoms, Conus,Venoms, Mollusc,Venoms, Mollusk,Venoms, Octopus,Venoms, Snail
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013111 Spider Venoms Venoms of arthropods of the order Araneida of the ARACHNIDA. The venoms usually contain several protein fractions, including ENZYMES, hemolytic, neurolytic, and other TOXINS, BIOLOGICAL. Araneid Venoms,Spider Toxin,Spider Toxins,Tarantula Toxin,Tarantula Toxins,Tarantula Venom,Araneid Venom,Spider Venom,Tarantula Venoms,Toxin, Spider,Toxin, Tarantula,Toxins, Spider,Toxins, Tarantula,Venom, Araneid,Venom, Spider,Venom, Tarantula,Venoms, Araneid,Venoms, Spider,Venoms, Tarantula
D015220 Calcium Channels Voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorized as L-, T-, N-, P-, Q-, and R-types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins. The L- and T-types are present throughout the cardiovascular and central nervous systems and the N-, P-, Q-, & R-types are located in neuronal tissue. Ion Channels, Calcium,Receptors, Calcium Channel Blocker,Voltage-Dependent Calcium Channel,Calcium Channel,Calcium Channel Antagonist Receptor,Calcium Channel Antagonist Receptors,Calcium Channel Blocker Receptor,Calcium Channel Blocker Receptors,Ion Channel, Calcium,Receptors, Calcium Channel Antagonist,VDCC,Voltage-Dependent Calcium Channels,Calcium Channel, Voltage-Dependent,Calcium Channels, Voltage-Dependent,Calcium Ion Channel,Calcium Ion Channels,Channel, Voltage-Dependent Calcium,Channels, Voltage-Dependent Calcium,Voltage Dependent Calcium Channel,Voltage Dependent Calcium Channels
D060848 Agatoxins A class of polyamine and peptide toxins which are isolated from the venom of spiders such as Agelenopsis aperta. alpha-Agatoxins,mu-Agatoxins,omega-Agatoxins,alpha Agatoxins,mu Agatoxins,omega Agatoxins

Related Publications

Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
December 1994, Annals of the New York Academy of Sciences,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
December 2003, Journal of bioenergetics and biomembranes,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
June 2005, General physiology and biophysics,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
November 1994, Nature,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
October 1977, Brain research,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
April 2004, Current drug targets. CNS and neurological disorders,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
August 1998, Journal of bioenergetics and biomembranes,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
August 1999, Current opinion in chemical biology,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
January 1993, International review of cytology,
Y Mori, and G Mikala, and G Varadi, and T Kobayashi, and S Koch, and M Wakamori, and A Schwartz
October 1986, British medical bulletin,
Copied contents to your clipboard!